Resources
Press Releases
Zeteo Biomedical To Present At SXSW Texas Global Health Security Innovation Demo Day Event
TEXGHS Global Health Security Event Features International Agenda of Companies and Speakers AUSTIN, TX – 15 March 2021 – Zeteo Biomedical will present its nasal vaccine packaging and delivery device technologies at the TEXGHS Global Health Security Demo Day scheduled...
Zeteo Biomedical Receives US Patent for Innovative Sublingual Delivery Device For Vaccines and Pharmaceuticals
Sublingual delivery is an emerging strategy for vaccines AUSTIN, TX – 10 March 2021 – Zeteo Biomedical a privately held, biomedical device company, announced today it has been awarded a United States Patent for its “Oral Delivery Device and Methods” (US Patent...
Zeteo Biomedical Introduces ZEOx1 AquilaMD™ Ophthalmic Drug Delivery System
Zeteo’s patient-centric ophthalmic delivery systems are designed for precise, self-administration of preservative free drugs and biopharmaceuticals AUSTIN, TX – 01 June 2020 -- (PR.com) – Zeteo Biomedical LLC announced today the availability of the ZEOx1 AquilaMD™...
Zeteo Biomedical receives NIH Award to develop a universal nasal flu vaccine in collaboration with the Iowa State University Nanovaccine Institute
Vaccines that can be quickly manufactured, deployed and self-administered at global scale volumes is crucial to protect global populations against pandemic virus threats AUSTIN, TX – 20 May 2020 –(pr.com)-- Zeteo Biomedical LLC, Inc., a privately held, medical device...
Presentations
Beyond the Bicep
Technology Platforms For Global Scale Packaging, Rapid Deployment and Self Administration Of Nasal Vaccines and Biomedical Countermeasures
The COVID-19 Vaccine (It’s Not a Shot in the Dark)
Vaccines have been around for quite a while, so why has the COVID-19 vaccine been such a hot-button topic? Why has the method of action, parameters for storage, and transportation been something so widely discussed? It’s great that this information is being provided...
Publications
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Partners
The Nanovaccine Institute is a consortium of 70 researchers at 20 universities, research institutes, national laboratories, and companies, coordinated by Iowa State University. Our research is a transdisciplinary merger of expertise in immunology, nanotechnology, materials science, microbiology, neuroscience, cancer biology, gerontology, clinical science, and social science. We are developing nanovaccines and nanotherapeutics for respiratory infections, neural disorders, tropical diseases, cancer, aging, and veterinary diseases.